In a move that underscores a growing investor interest in artificial intelligence applications within healthcare, Cathie Wood's Ark Invest has significantly increased its stake in Tempus AI Inc., while reducing its exposure to Meta Platforms Inc. According to a report from Benzinga, Ark Invest purchased shares in Tempus AI valued at approximately $3.97 million. This transaction, detailed in the firm's latest trade disclosures, reflects Wood's ongoing pivot toward innovative sectors like medical AI, even as established tech giants like Meta continue to dominate headlines.
Tempus AI, which trades under the ticker TEM on the Nasdaq, specializes in using AI to analyze vast amounts of clinical and molecular data to advance precision medicine, particularly in oncology. The timing of Ark's investment aligns closely with Tempus' recent partnership announcement with Daiichi Sankyo, a major Japanese pharmaceutical company. This collaboration, unveiled earlier this month, aims to harness AI models for biomarker discovery, focusing on improving patient selection in clinical trials for cancer treatments. By leveraging Tempus' extensive database of over six million de-identified patient records, the partnership seeks to accelerate the development of targeted therapies, potentially increasing the success rates of new oncology drugs.
Cathie Wood, the founder and CEO of Ark Invest, has long been known for her bold bets on disruptive technologies. Since launching her flagship ARK Innovation ETF (ARKK) in 2014, Wood has championed investments in genomics, robotics, and now increasingly in AI-driven healthcare solutions. Ark's funds, which manage billions in assets, have seen volatile performance, with ARKK posting significant gains during the early days of the pandemic-fueled tech boom before facing sharp declines amid rising interest rates. Despite these ups and downs, Wood remains a vocal advocate for long-term growth in AI, often citing its potential to transform industries like medicine.
The decision to load up on Tempus shares comes amid a broader strategy shift at Ark, where the firm appears to be dialing back on some big tech holdings. Benzinga reported that Ark trimmed its position in Meta Platforms, though specific share volumes and values for the Meta sale were not detailed in the disclosures reviewed. Meta, the parent company of Facebook, Instagram, and WhatsApp, has been a staple in many growth-oriented portfolios due to its massive user base and advertising revenue. However, with a market capitalization exceeding $1 trillion, some investors like Wood may view it as overvalued compared to nimbler AI upstarts in specialized fields.
This isn't the only adjustment in Ark's portfolio. In related trades, Ark's ARKK fund offloaded 463,363 shares of Archer Aviation Inc. (NYSE: ACHR), a company developing electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Archer's stock closed at $5.56 on the day of the transaction, marking a modest gain of 0.91%. The sale, which reduced Ark's exposure to the nascent flying taxi sector, comes as Archer faces regulatory hurdles and competition from players like Joby Aviation. Wood has previously expressed enthusiasm for autonomous mobility, but recent market dynamics may have prompted this reevaluation.
Additionally, Ark's ARKK and ARKW funds together sold 21,100 shares of Block Inc. (NYSE: SQ), the parent of Square and Cash App, known for its fintech innovations in payments and blockchain. Block's shares ended the trading session at $60.01, up 0.2%. This divestment signals a potential cooling on certain fintech plays, especially as economic uncertainties loom with persistent inflation and shifting consumer spending patterns. Block, formerly known as Square, has been a long-time holding in Ark's innovation-focused funds, but its recent struggles with cryptocurrency volatility may have influenced the decision.
Tempus AI itself is a relatively new public entity, having gone public via a SPAC merger in mid-2024. Founded in 2015 by Eric Lefkofsky, whose wife was diagnosed with cancer, Tempus has raised over $1.3 billion in funding and partners with more than 2,000 healthcare institutions. Its platform integrates genomic sequencing, electronic health records, and AI algorithms to provide physicians with actionable insights for personalized treatment plans. The collaboration with Daiichi Sankyo, which focuses on antibody-drug conjugates for solid tumors, could be a game-changer, as AI-driven patient stratification has shown promise in reducing trial failures, which plague up to 90% of oncology drug developments according to industry estimates.
Industry analysts have taken note of Ark's move. While Benzinga described it as Wood "choosing medical AI over Mark Zuckerberg," the trade highlights a broader trend among institutional investors seeking alpha in healthcare tech. Venture capital funding for AI in drug discovery reached $5.2 billion in 2023, per PitchBook data, with oncology remaining a prime focus due to the global cancer burden affecting nearly 20 million new cases annually, as reported by the World Health Organization.
From Meta's perspective, the social media giant continues to invest heavily in AI, with CEO Mark Zuckerberg announcing plans to build advanced models like Llama 3 to compete with OpenAI. However, Ark's reduction in Meta shares may reflect concerns over regulatory pressures, including antitrust scrutiny from the Federal Trade Commission, and slowing ad growth in a post-iOS privacy era. Meta's stock has risen over 70% year-to-date, but Wood's strategy emphasizes higher-risk, higher-reward opportunities in emerging AI niches.
Ark Invest's trading activity is closely watched by retail and institutional investors alike, given Wood's influence on meme stocks and innovation themes. The firm discloses its trades daily after market close, providing transparency into its conviction plays. The Tempus purchase was executed through ARKK and other thematic ETFs, bringing Ark's total exposure to the stock to a more substantial position, though exact pre-trade holdings weren't specified in the Benzinga report.
Looking ahead, the implications of this shift could ripple through both sectors. For Tempus, Ark's backing validates its technology at a time when the company is expanding its AI tools for real-world evidence generation, which helps pharma companies navigate post-approval challenges. Daiichi Sankyo, with its robust pipeline including Enhertu for breast cancer, stands to benefit from Tempus' data trove, potentially shortening development timelines from the typical 10-15 years.
On the flip side, divestments like those in Archer and Block underscore the challenges in speculative areas. Archer, backed by United Airlines and Stellantis, aims for commercial eVTOL flights by 2025, but FAA certification remains a wildcard. Block, meanwhile, is pivoting toward embedded finance, but faces stiff competition from PayPal and traditional banks digitizing services.
As markets evolve, Cathie Wood's latest trades serve as a barometer for where she sees the next wave of innovation. With AI permeating healthcare, her bet on Tempus could pay off if the sector delivers on its promises of more efficient, equitable care. Investors will be watching subsequent filings for further clues on Ark's trajectory, especially as earnings seasons approach and geopolitical tensions influence global supply chains for tech and pharma.
In the end, this portfolio rebalancing illustrates the dynamic nature of growth investing, where conviction in medical breakthroughs may eclipse the allure of social media empires. Whether Tempus emerges as the next big winner in Ark's roster remains to be seen, but for now, Wood's actions speak volumes about her vision for the future of AI.